



**Indian College of  
Radiation Oncology (ICRO)**  
*Academic Wing of*  
**Association of Radiation Oncologists  
of India (AROI)**

**50<sup>TH</sup> ICRO PG Teaching Program**

30<sup>th</sup> & 31<sup>st</sup> August 2025

**On**


**“Landmark Trials & Practice Changing Evidence  
in Breast, H & N, GI and Gynec Cancers ”**

**Organising Institute**

Department of Radiation Oncology,  
Shri Guru Ram Rai Institute of Medical and Health Sciences,  
Dehradun

**Venue**

Hospital Auditorium, 3<sup>rd</sup> floor, Middle Block, Shri Mahant Indires Hospital,  
Shri Guru Ram Rai Institute of Medical and Health Sciences,  
Dehradun



This educational initiative is  
supported by



**SUN**  
ONCOLOGY

a SUN PHARMA division

## Course Goal

The proposed course 50<sup>th</sup> ICRO PG Teaching on the Landmark Trials & Practice - Changing Evidence in Breast, Head and Neck, GI and Gynec Cancers is specifically designed for radiotherapy residents to navigate the dynamic world of evidence-based practice in four critical oncological domains of the most common cancers seen in India. Through systematic examination of pivotal trials and their clinical implications, participants will develop the analytical skills necessary to critically evaluate emerging evidence and integrate practice-changing findings into contemporary patient care.

By examining both historical milestones and recent breakthrough trials, participants will gain invaluable insights into how evidence-based medicine continues to refine and optimize outcomes for patients across these four major cancer sites, preparing them to become thoughtful practitioners capable of adapting to the ever-changing field of radiation oncology.

## Organising Institute

Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun was propelled to success by the present Sajjada Nashin Sri Mahant Devendra Das Ji, the successor of the highest seat of Udaseen Sect. He dedicated this institution to the name of Sri Guru Ram Rai ji Maharaj, the eldest son of the seventh Guru of the Sikhs- Sri Har Raiji. Shri Guru Ram Rai Ji established his DERA in Doon valley which later became popular as DEHRA and thus Dehradun owes its name and history to the emergence of Sri Guru Ram Raiji's "Dera" in 1676 in area now called Dehradun.

SGRRIM & HS is stretched over a gigantic 30 acres of land. The institute have 150 seats in MBBS and 165 seats in Postgraduate(MD/MS). All super-specialties department are fully functional with 19 seats of DM and MCh. A team of dedicated and learned faculty makes this institution a center of excellence for medical education

Under the guidance of the visionary Chairman the institute is coming up with a state of the art Comprehensive Cancer Institute. This will be a tertiary cancer treatment center comprising of 300 beds and will be equipped with Radiation, Robotic Surgical Oncology, Medical Oncology, Nuclear Medicine and BMT services.

## AROI Office Bearers



**Chair, AROI**  
**Prof. (Dr.) Manoj Gupta,**  
Email: mkgupta62@yahoo.co.in  
Mobile: +91 98161 37344



**President, AROI**  
**Prof. (Dr.) S. N. Senapati**  
Email: snsenapati2007@gmail.com  
Mobile: +91 94370 31718



**President Elect, AROI**  
**Prof. (Dr.) C.S. Madhu**  
Email: dr.csmadhu@gmail.com  
Mobile: +91 93871 03803



**Secretary General, AROI**  
**Dr. V Srinivasan**  
Email: vsrinivasan09@gmail.com  
Mobile: +91 98410 22366

## ICRO Office Bearers



**Chairman**  
**Prof. (Dr.) Sarbani Ghosh Laskar**  
Email: sarbanilaskar@gmail.com  
Mobile: +91 98208 34386



**Vice Chairman**  
**Dr. Gautam K Sharan**  
Email: dr.gautamsharan@gmail.com  
Mobile: +91 93263 23109



**Secretary**  
**Dr. Pooja Nandwani Patel**  
Email: drpoojanandwani@gmail.com  
Mobile: +91 98257 39897

## Program Co-ordinators



**Dr. Manoj Gupta,**  
Director,  
SGRRIM & HS, Dehradun  
Email: mkgupta62@yahoo.co.in



**Dr. Rachit Ahuja**  
Assistant Professor, Department of Radiotherapy,  
SGRRIM & HS, Dehradun  
Email: rachitahuja.dr@gmail.com

# REGISTRATION

Scan the below QR code to register for the program

SCAN ME



## For Indian students

- 2<sup>nd</sup> and 3<sup>rd</sup> year MD / DNB (Radiation Oncology) Post Graduate students to be nominated by the Head of the Departments / Institutes.
- AROI membership is mandatory to be part of the program. If not registered, please register and attach the same while filling the QR code.
- Registration will be based upon first-cum-first-served basis.
- Last date for submission of application : 15<sup>th</sup> August 2025.
- Candidates will have to pay Registration fee of Rs. 1,500/- upto 15<sup>th</sup> of August (Post 15<sup>th</sup> of August Rs. 2000) through online payment mode only. Account details for the same mentioned below.

Bank: State Bank of India

Account Name: AROI - ICRO

Account No: 39535445525

Address: Millerganj, Ludhiana

IFSC CODE: SBIN0000731

- After making the payment, upload the payment receipt along with the registration details through QR code.
- It is compulsory for the students to attend on both the days to avail the certificate distributed during the end of program. Failing to this no reasons will be entertained and the respective head of the department will be intimated too if the student is found absent on any of the days.

## For FARO members & SAARC countries:

- Registration fee is 30USD
- After making the payment, please mail the payment receipt to [secretaryicro@gmail.com](mailto:secretaryicro@gmail.com), & [secretaryaroi@gmail.com](mailto:secretaryaroi@gmail.com)
- For any correspondence please contact Secretary, ICRO at [secretaryicro@gmail.com](mailto:secretaryicro@gmail.com) or The decision of ICRO body will be final and binding



# AGENDA

**Day-1 : 30<sup>th</sup> August, Saturday 2025**

S.No	Time	Topic
<b>SESSION - 1 - HEAD AND NECK CANCERS</b>		
1	09:00-09:30 AM	How to read and dissect Trial and its relevance in clinical practice
2	09:30-10:15 AM	Clinical trials on PORT in Early OSCC and dose fractionation, Node negative, OCAT, deintensification strategies: HPV +, MSKCC protocol: RO 30
3	10:15-11:00 AM	Clinical trials on Organ preservation strategy and role of Induction chemotherapy: MACH NC update and Beyond
	11:00-11:45 AM	<b>INAUGURATION AND TEA BREAK</b>
4	11:45-12:30 AM	Role of Immunotherapy as first line in HNC Checkmate 141, Keynote 41, Keynote 048, Keynote 689, Nivopost op
<b>SESSION - 2 - BREAST CANCERS</b>		
5	12:30-01:00 PM	Hypofractionation Trials on Breast cancer beyond START: Are we ready now? FAST & FAST-Forward
6	01:00-01:30 PM	Clinical trials on Nodal irradiation and dose fractionation NSABP B-51, RTOG 1304, FAST-Forward subgroup, MA.20, EORTC 22
7	01:30-02:00 PM	Clinical approach on Oligometastatic Breast cancer Are we treating them with Radical intent: Evidence?
	02:00-03:00 PM	<b>LUNCH</b>
8	03:00-03:30 PM	PMRT trials – EBCTCG, SUPREMO and others
<b>SESSION - 3 - GI CANCERS</b>		
9	03:30-04:00 PM	Is RT still relevant in gastroesophageal cancer: CROSS, FLOT, ESOPEC, TOPGEAR, ARTIST II, CRITICS I
10	04:00-04:30 PM	Redefining neoadjuvant treatment in rectal cancer: Prospect, updated Rapido in 2025, Prodigy, Aristotle trial and PRIME-RT trials
	04:30-05:00 PM	<b>TEA BREAK</b>
11	05:00-05:30 PM	Non-operative management for Rectal Cancer: Discovering Whom, How and when by Opera, Opra, Star-Trec, German Rectal Cancer Study Group (CAO/ARO/AIO-16)
12	05:30-06:00 PM	Is it time to deintensify treatment for Anal Cancer: Decrease and ACT 4 trial



# AGENDA

Day-2 : 31 <sup>st</sup> August, Sunday 2025		
S.No	Time	Topic
<b>SESSION - 3 - GI CANCERS</b>		
1	09:00-09:30 AM	Gall bladder cancer: India defines treatment for an Indian Cancer: GECOR-GB, RACE-GB & POLCA GB
<b>SESSION - 4 - GYNECOLOGICAL CANCERS</b>		
2	09:30-10:00 AM	PORTEC trials - evolution in management of EC
3	10:00-10:30 AM	Neoadjuvant and adjuvant trials in Carcinoma Cervix Interlace Trial and beyond
4	10:30-11:00 AM	Improving therapeutic outcomes with radiotherapy in cervical cancer EMBRACE and beyond
	11:00-11:30 AM	<b>TEA BREAK</b>
5	11:30 -12:00 AM	Current evidence for practice of immunotherapy with concurrent chemoradiation in cervical cancer (KEYNOTE-A18 Trial and CALLA trial)
6	12:00 -12:30 AM	3DCRT versus IMRT in cervical cancers: PARCER trial and beyond - what are the lessons learnt
7	12:30 -01:00 PM	<b>QUIZ</b>
8	01:00 -01:30 PM	Feedback, results of quiz, certificate distribution and vote of thanks
	01:30 -02:30 PM	<b>LUNCH</b>